Blood-based Aβ biomarkers using immunoprecipitation-mass spectrometry assay: Methodological details and processes for its clinical application

Akinori Nakamura

Department of Biomarker Research, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology

Accurate detection of brain Aβ pathology is important for early detection of Alzheimer’s disease that enables earlier interventions.　Therefore, there have been strong needs for blood-based Aβ biomarkers which are less costly and less invasive compared with CSF testing and/or PET scans.　Recent technological advances in fluid biochemical assays are showing promising results for blood-based Aβ biomarkers.　Among several methods, Immunoprecipitation-mass spectrometry （IP-MS） is considered one of the most sensitive and accurate assays.　In this paper, I introduce about the methodological details of IP-MS, and processes for its clinical application.

Address correspondence to Dr. Akinori Nakamura, Department of Biomarker Research, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology （7-430, Morioka-cho, Obu-shi, Aichi 474-8511, Japan）